Theravance Biopharma financials at a glance

+ Portfolio

The revenue of Theravance Biopharma is reported as 0.05742 billion Dollars in the fiscal year 2023. The earnings were -0.39 Dollars per share in 2023, which was 35 higher than 2022. And about -0.00249 billion Dollars are reported as free cash flow in the financials of Theravance Biopharma 2023. No dividends were paid to the shareholders of the Theravance Biopharma stock NasdaqGM:TBPH in the financial year 2023.

$57.42M

Revenue

$-0.39

Earnings Per Share

29.26%

Gross Margin %

$-27.00M

Free Cash Flow

Revenue

57.42

Earnings Per Share

-0.39

Gross Margin %

29.26

Free Cash Flow

-27.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Rev.	Revenue	N/A	$57.42M	$51.35M	$55.31M	$71.86M	$73.41M	$60.37M	$15.39M	$48.65M	$42.13M	$11.69M
GM %	Gross Margin %	12.57%	29.26%	-23.46%	-,250.12%	-,263.16%	-,198.65%	-,234.71%	0.00%	-,197.25%	-,217.67%	0.00%
OM	Operating Margin	-,118.30%	-92.80%	-,154.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.95	$-0.39	$-0.60	$-2.58	$-4.22	$-4.25	$-3.99	$-5.45	$-4.26	$-5.34	$-7.46
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%
Sha.	Shares	N/AM	48.16M	62.86M	74.7M	64.33M	62.52M	55.58M	54.38M	52.86M	38.43M	33.8M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$-,207.86M	$-,250.40M	$-,238.20M	$-,112.87M	$-,201.05M	$-98.99M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$-27.00M	$0.00M	$-,211.26M	$-,257.02M	$-,241.37M	$-,170.73M	$-,203.46M	$-,101.12M	$0.00M	$-,178.26M
FCFS	Free Cash Flow Per Share	$-2.55	$-0.53	$-2.55	$-3.04	$-4.12	$-4.34	$-2.23	$-3.89	$-2.26	$-5.02	$-5.61

Theravance Biopharma financials at a glance

Financials

Discover